NASDAQ:SPRO Spero Therapeutics - SPRO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.85 +0.02 (+1.09%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.81▼$1.8750-Day Range$1.55▼$2.0052-Week Range$0.68▼$12.04Volume95,983 shsAverage Volume329,919 shsMarket Capitalization$64.87 millionP/E RatioN/ADividend YieldN/APrice Target$6.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spero Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside242.3% Upside$6.33 Price TargetShort InterestHealthy1.90% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-0.80Upright™ Environmental ScoreNews Sentiment0.96Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.48) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.61 out of 5 starsMedical Sector116th out of 1,055 stocksPharmaceutical Preparations Industry48th out of 518 stocks 3.3 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.33, Spero Therapeutics has a forecasted upside of 242.3% from its current price of $1.85.Amount of Analyst CoverageSpero Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.90% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 21.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 3.3 News and Social Media Coverage News SentimentSpero Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Spero Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.36% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions57.38% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($2.48) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spero Therapeutics (NASDAQ:SPRO) StockSpero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comFY2022 EPS Estimates for Spero Therapeutics, Inc. Increased by HC Wainwright (NASDAQ:SPRO)January 26, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Spero Therapeutics (SPRO)February 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 24, 2023 | americanbankingnews.comHead to Head Contrast: Spero Therapeutics (NASDAQ:SPRO) vs. Puma Biotechnology (NASDAQ:PBYI)January 14, 2023 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 85%December 24, 2022 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO)November 22, 2022 | finance.yahoo.comSpero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx ConferenceNovember 16, 2022 | finance.yahoo.comSpero Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsFebruary 1, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 16, 2022 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business UpdateNovember 15, 2022 | 247wallst.comGlaxosmithkline Ups Stake in Spero Therapeutics Inc (SPRO)November 15, 2022 | seekingalpha.comSpero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comSpero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business UpdateNovember 12, 2022 | msn.comEarnings Outlook For Spero TherapeuticsNovember 7, 2022 | finance.yahoo.comSpero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022November 2, 2022 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?October 19, 2022 | finance.yahoo.comSpero Therapeutics to Present Data at IDWeek 2022October 10, 2022 | msn.comHow Is The Market Feeling About Spero Therapeutics?October 5, 2022 | morningstar.comSpero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program | MorningstarOctober 3, 2022 | seekingalpha.comSpero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder ValueOctober 3, 2022 | finance.yahoo.comSpero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 ProgramSeptember 25, 2022 | finance.yahoo.comThis Infection-Fighting Biotech Is Recovering NicelySeptember 23, 2022 | finance.yahoo.comSpero (SPRO) Skyrockets 168% on Licensing Deal With GSKSeptember 23, 2022 | benzinga.comSpero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On SalesforceSeptember 22, 2022 | msn.comGSK eyes Spero's experimental urinary tract infection drug, takes stakeSeptember 22, 2022 | markets.businessinsider.comGSK To Receive Licence From Spero To Develop, Commercialise Tebipenem Pivoxil HBrSeptember 22, 2022 | msn.comGSK takes stake in Spero in deal for experimental UTI treatmentSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Company Calendar Last Earnings11/14/2022Today1/31/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees146Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.33 High Stock Price Forecast$8.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+242.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,760,000.00 Net Margins-1,162.35% Pretax Margin-1,162.35% Return on Equity-186.94% Return on Assets-92.07% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$17.67 million Price / Sales3.67 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.68Miscellaneous Outstanding Shares35,067,000Free Float33,538,000Market Cap$64.87 million OptionableOptionable Beta0.79 Key ExecutivesDr. Ankit Mahadevia M.D. (Age 42)MBA, Co-Founder, Pres, CEO & Director Comp: $924.28kMr. Satyavrat Shukla C.F.A. (Age 51)CFO & Treasurer Comp: $788.84kTed JenkinsVP & Head of Investor RelationsMs. Tamara Lynn Joseph L.L.M. (Age 60)Chief Legal Officer Mr. James P. BradyChief Human Resource OfficerMr. Timothy Keutzer (Age 55)Chief Devel. Officer Dr. Ian A. CritchleyHead of Clinical MicrobiologyDr. Susannah Walpole Ph.D.Head of Clinical OperationsDr. Angela Talley M.D.Sr. VP of Clinical Devel.Dr. Kamal Hamed M.B.A.M.D., M.P.H., Chief Medical OfficerMore ExecutivesKey CompetitorsOrgenesisNASDAQ:ORGSLeap TherapeuticsNASDAQ:LPTXGenprexNASDAQ:GNPXOncternal TherapeuticsNASDAQ:ONCTReneo PharmaceuticalsNASDAQ:RPHMView All CompetitorsInsiders & InstitutionsAnson Funds Management LPBought 1,473,872 shares on 11/16/2022Ownership: 4.203%Alphabet Inc.Bought 889,979 shares on 11/16/2022Ownership: 2.538%Jane Street Group LLCBought 15,496 shares on 11/16/2022Ownership: 0.044%State Street CorpSold 9,073 shares on 11/15/2022Ownership: 0.260%Citadel Advisors LLCSold 36,600 shares on 11/15/2022Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SPRO Stock - Frequently Asked Questions Should I buy or sell Spero Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks. What is Spero Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued 12-month price objectives for Spero Therapeutics' shares. Their SPRO share price forecasts range from $5.00 to $8.00. On average, they anticipate the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts. How have SPRO shares performed in 2023? Spero Therapeutics' stock was trading at $1.73 at the beginning of the year. Since then, SPRO shares have increased by 6.9% and is now trading at $1.85. View the best growth stocks for 2023 here. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 667,900 shares, a decline of 21.4% from the December 31st total of 849,400 shares. Based on an average daily trading volume, of 617,400 shares, the short-interest ratio is presently 1.1 days. View Spero Therapeutics' Short Interest. When is Spero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our SPRO earnings forecast. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. The business earned $2.01 million during the quarter, compared to analyst estimates of $6.75 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 186.94% and a negative net margin of 1,162.35%. Is Spero Therapeutics a good dividend stock? Spero Therapeutics (NASDAQ:SPRO) pays an annual dividend of $0.06 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for SPRO. What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin and Sath Shukla. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $1.85. How much money does Spero Therapeutics make? Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $64.87 million and generates $17.67 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. How many employees does Spero Therapeutics have? The company employs 146 workers across the globe. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com. This page (NASDAQ:SPRO) was last updated on 2/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.